s in cats; and Fortekor, for the treatment of congestive heart failure in dogs and reduction of proteinurea associated with chronic kidney disease in cats. Strategy The company’s Elanco animal health innovation strategy is focused on identifying and developing promising technologies and potential products from internal and external sources to meet unmet veterinary needs. Marketing The company sells majority of its products worldwide. Human Pharmaceuticals—U.S.: In the U.S., the company distributes human pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In 2015, three wholesale distributors in the U.S.—AmerisourceBergen Corporation, McKesson Corporation, and Cardinal Health, Inc.—each accounted for between 8 percent and 19 percent of the company’s consolidated total revenue. The company promotes its major human pharmaceutical products in the U.S. through sales representatives who call upon physicians and other health care professionals. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. Human Pharmaceuticals—Outside the U.S.: Outside the U.S, the company promotes its human pharmaceutical products primarily through sales representatives. In various countries in which the company operates, it maintains its own sales organizations, but in some smaller countries that the company markets its products through independent distributors. Research and Development For the year ended December 31, 2015, the company’s research and development expenses were $4.80 billion. Human Pharmaceutical Marketing Collaborations Certain of the company’s human pharmaceutical products are marketed in arrangements with other pharmaceutical companies, including: The company and Boehringer Ingelheim have a diabetes alliance under which the company jointly develops and commercializes Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, and Basaglar in major markets. The company co-promotes Cymbalta in Japan with Shionogi & Co. Ltd. Through September 2015, Erbitux was marketed in the U.S. and Canada by Bristol-Myers Squibb (BMS). Effective October 1, 2015, BMS transferred to the company all commercialization rights for Erbitux in those two countries. Outside the U.S. and Canada, Erbitux is commercialized by Merck KGaA, and the company receives royalties from Merck KGaA. Effient is co-promoted with the company by Daiichi Sankyo Co., Ltd. in the U.S., Brazil, Mexico, and certain other countries. The company retains sole marketing rights in Canada, Australia, Russia, and certain other countries. Daiichi Sankyo Co., Ltd. retains sole marketing rights in Japan and certain other countries. Animal Health Products The company’s Elanco animal health business unit employs field salespeople throughout the U.S. and has an extensive sales force outside the U.S. Elanco sells its products primarily to wholesale distributors. Elanco promotes its products primarily to producers and veterinarians for food animal products and to veterinarians for companion animal products. Elanco also advertises certain companion animal products directly to pet owners. Patents, Trademarks, and Other Intellectual Property Rights Intellectual Property Portfolio The relevant U.S. patent protection or data protection for the company’s patent-protected marketed products includes Alimta, which is protected by a compound patent (2016) plus pediatric exclusivity (2017), and a vitamin regimen patent (2021) plus pediatric exclusivity (2022); Cialis that is protected by compound and use patents (2017); Cyramza, which is protected by biologics data package protection (2026); Effient that is protected by a compound patent (2017) and patents covering methods of using Effient with aspirin (2023); Forteo is protected by patents primarily covering its formulation and related processes (2018) and use patents (2019); Jardiance, and the related combination products Glyxambi and Synjardy, are protected by a compound patent (202
eli lilly & co (LLY:Frankfurt)
Lilly Corporate Center
Indianapolis, IN 46285
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for LLY.|
|View Industry Companies|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.